$CTKB
Cytek Biosciences, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004256 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $38.89M $34.38M $25.10M
YoY Change 36.98%
Cost Of Revenue $15.26M $13.10M $9.480M
YoY Change 38.18%
Gross Profit $23.64M $21.28M $15.62M
YoY Change 36.25%
Gross Profit Margin 60.77% 61.89% 62.23%
Selling, General & Admin $15.24M $12.30M $5.529M
YoY Change 122.5%
% of Gross Profit 64.49% 57.82% 35.41%
Research & Development $7.076M $6.078M $3.376M
YoY Change 80.04%
% of Gross Profit 29.94% 28.57% 21.62%
Depreciation & Amortization $685.0K $192.0K $163.0K
YoY Change 13.6% 17.79%
% of Gross Profit 2.9% 0.9% 1.04%
Operating Expenses $22.32M $18.38M $8.905M
YoY Change 106.4%
Operating Profit $1.317M $2.897M $6.711M
YoY Change -56.83%
Interest Expense -$474.0K $441.0K $2.000K
YoY Change 21950.0%
% of Operating Profit -35.99% 15.22% 0.03%
Other Income/Expense, Net -$399.0K -$822.0K $186.0K
YoY Change -541.94%
Pretax Income $444.0K $2.075M $6.897M
YoY Change -69.91%
Income Tax $1.609M $655.0K $357.0K
% Of Pretax Income 362.39% 31.57% 5.18%
Net Earnings -$1.191M $1.420M $6.540M
YoY Change -78.29%
Net Earnings / Revenue -3.06% 4.13% 26.06%
Basic Earnings Per Share $0.00 $0.05
Diluted Earnings Per Share -$8.514K $0.00 $0.05
COMMON SHARES
Basic Shares Outstanding 133.7M 108.3M 28.70M
Diluted Shares Outstanding 113.6M 31.06M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $364.6M $376.8M
YoY Change
Cash & Equivalents $364.6M $376.8M $35.53M
Short-Term Investments $0.00
Other Short-Term Assets $708.0K $95.00K
YoY Change 59.1%
Inventory $32.17M $27.51M
Prepaid Expenses
Receivables $29.76M $29.45M
Other Receivables -$127.0K $1.373M
Total Short-Term Assets $431.7M $439.8M
YoY Change 106.95%
LONG-TERM ASSETS
Property, Plant & Equipment $5.851M $4.982M
YoY Change 173.41%
Goodwill $10.14M $476.0K
YoY Change 2031.09%
Intangibles $4.739M $361.0K
YoY Change 1629.56%
Long-Term Investments
YoY Change
Other Assets $1.665M $1.297M
YoY Change 52.89%
Total Long-Term Assets $31.57M $14.49M
YoY Change 178.0%
TOTAL ASSETS
Total Short-Term Assets $431.7M $439.8M
Total Long-Term Assets $31.57M $14.49M
Total Assets $463.3M $454.3M
YoY Change 110.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.034M $3.927M
YoY Change
Accrued Expenses $15.25M $10.75M
YoY Change 68.56%
Deferred Revenue $16.87M $13.63M
YoY Change 136.92%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.18M $30.01M
YoY Change 25.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.204M $737.0K
YoY Change 63.36%
Total Long-Term Liabilities $1.204M $737.0K
YoY Change 63.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.18M $30.01M
Total Long-Term Liabilities $1.204M $737.0K
Total Liabilities $57.92M $51.13M
YoY Change 38.94%
SHAREHOLDERS EQUITY
Retained Earnings -$19.61M -$18.42M
YoY Change -13.27%
Common Stock $126.0K $125.0K
YoY Change 447.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $405.4M $403.2M -$27.39M
YoY Change
Total Liabilities & Shareholders Equity $463.3M $454.3M
YoY Change 110.61%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$1.191M $1.420M $6.540M
YoY Change -78.29%
Depreciation, Depletion And Amortization $685.0K $192.0K $163.0K
YoY Change 13.6% 17.79%
Cash From Operating Activities $5.448M $1.161M
YoY Change -64.05%
INVESTING ACTIVITIES
Capital Expenditures -$1.296M -$1.308M
YoY Change -16.22%
Acquisitions
YoY Change
Other Investing Activities -$17.00M $0.00
YoY Change
Cash From Investing Activities -$18.30M -$1.308M
YoY Change 1082.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 17.00K 217.1M
YoY Change -99.99%
NET CHANGE
Cash From Operating Activities 5.448M 1.161M
Cash From Investing Activities -18.30M -1.308M
Cash From Financing Activities 17.00K 217.1M
Net Change In Cash -12.83M 216.9M
YoY Change -109.42%
FREE CASH FLOW
Cash From Operating Activities $5.448M $1.161M
Capital Expenditures -$1.296M -$1.308M
Free Cash Flow $6.744M $2.469M
YoY Change -59.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001831915
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
ctkb Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
ctkb Interest Expenses For Accretion Of Legal Settlement Liabilities
InterestExpensesForAccretionOfLegalSettlementLiabilities
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 ctkb Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
ctkb Payment For Additional Investment In Cytek Japan Net Of Cash Acquired
PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
ctkb Intangible Asset In Accrued Expense
IntangibleAssetInAccruedExpense
dei Amendment Flag
AmendmentFlag
false
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40632
dei Entity Address City Or Town
EntityAddressCityOrTown
Fremont
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94538
dei City Area Code
CityAreaCode
877
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6742000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4000
dei Entity Registrant Name
EntityRegistrantName
CYTEK BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2547526
dei Entity Address Address Line1
EntityAddressAddressLine1
47215 Lakeview Blvd
dei Local Phone Number
LocalPhoneNumber
922-9835
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
CTKB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
133725908
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376771000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165231000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29450000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16990000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
888000
CY2021Q3 us-gaap Inventory Net
InventoryNet
27511000
CY2020Q4 us-gaap Inventory Net
InventoryNet
23018000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6094000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2495000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
439826000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
208622000
CY2021Q3 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7378000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
7378000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4982000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2140000
CY2021Q3 us-gaap Goodwill
Goodwill
476000
CY2020Q4 us-gaap Goodwill
Goodwill
476000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
361000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
274000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1297000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1089000
CY2021Q3 us-gaap Assets
Assets
454320000
CY2020Q4 us-gaap Assets
Assets
219979000
CY2021Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3927000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2944000
CY2021Q3 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
7405000
CY2020Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
6253000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10753000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9048000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2044000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4626000
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5885000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3665000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30014000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26536000
CY2021Q3 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
12633000
CY2020Q4 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
10959000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7741000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3456000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
737000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
737000
CY2021Q3 us-gaap Liabilities
Liabilities
51125000
CY2020Q4 us-gaap Liabilities
Liabilities
41688000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
153329500
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
133725741
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
133725741
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31241916
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31241916
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
125000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
420600000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6491000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18415000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22607000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
570000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
65000
CY2021Q3 ctkb Noncontrolling Interest In Consolidated Subsidiary
NoncontrollingInterestInConsolidatedSubsidiary
315000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
403195000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16028000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
454320000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
219979000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34376000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25096000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89056000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62220000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13099000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9480000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33548000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29959000
CY2021Q3 us-gaap Gross Profit
GrossProfit
21277000
CY2020Q3 us-gaap Gross Profit
GrossProfit
15616000
us-gaap Gross Profit
GrossProfit
55508000
us-gaap Gross Profit
GrossProfit
32261000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6078000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3376000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17366000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9308000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6553000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3838000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16406000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10428000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5749000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1691000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13896000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
18380000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
8905000
us-gaap Operating Expenses
OperatingExpenses
47668000
us-gaap Operating Expenses
OperatingExpenses
26478000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2897000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
6711000
us-gaap Operating Income Loss
OperatingIncomeLoss
7840000
us-gaap Operating Income Loss
OperatingIncomeLoss
5783000
CY2021Q3 us-gaap Interest Expense
InterestExpense
441000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2000
us-gaap Interest Expense
InterestExpense
1249000
us-gaap Interest Expense
InterestExpense
3000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
us-gaap Investment Income Interest
InvestmentIncomeInterest
31000
us-gaap Investment Income Interest
InvestmentIncomeInterest
105000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-393000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
185000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1128000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
543000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-822000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
186000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2346000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
645000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2075000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6897000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5494000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6428000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
655000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
357000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1302000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7384000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
1420000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
6540000
us-gaap Net Income Loss
NetIncomeLoss
4192000
us-gaap Net Income Loss
NetIncomeLoss
13812000
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-1074000
CY2020Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-5094000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-4192000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-11171000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
346000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1446000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2641000
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.05
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.09
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.05
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.09
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108322433
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28700005
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57534080
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28551126
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113637377
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31058757
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62095275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30763586
CY2021Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
1420000
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
6540000
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
4192000
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
13812000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
34000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
145000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
505000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
49000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1454000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6685000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4697000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13861000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16028000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
196000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
456000
CY2021Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
202000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
102000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
315000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-14757000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
166000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
667000
CY2021Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
269000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
2670000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-10985000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
264000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2455000
CY2021Q3 ctkb Issuance Of Common Stock Upon Initial Public Offering Net Of Underwriting Discounts And Commissions And Other Offering Costs Value
IssuanceOfCommonStockUponInitialPublicOfferingNetOfUnderwritingDiscountsAndCommissionsAndOtherOfferingCostsValue
215689000
CY2021Q3 ctkb Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Initial Public Offering Value
ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponInitialPublicOfferingValue
194318000
CY2021Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
34000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
1420000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
403195000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-41701000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105000
CY2020Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-77000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-839000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-42499000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
109000
CY2020Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-19000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
8111000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-34297000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
95000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
126000
CY2020Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
145000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
6540000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-27391000
us-gaap Profit Loss
ProfitLoss
4192000
us-gaap Profit Loss
ProfitLoss
13812000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
557000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
445000
us-gaap Share Based Compensation
ShareBasedCompensation
3578000
us-gaap Share Based Compensation
ShareBasedCompensation
340000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
40000
us-gaap Inventory Write Down
InventoryWriteDown
-333000
us-gaap Inventory Write Down
InventoryWriteDown
1199000
ctkb Interest Expenses For Accretion Of Legal Settlement Liabilities
InterestExpensesForAccretionOfLegalSettlementLiabilities
1215000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11647000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
814000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4838000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5421000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5002000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8980000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
486000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1663000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2099000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1760000
ctkb Increase Decrease In Legal Settlement Liabilities
IncreaseDecreaseInLegalSettlementLiabilities
1612000
ctkb Increase Decrease In Legal Settlement Liabilities
IncreaseDecreaseInLegalSettlementLiabilities
1700000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6637000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1137000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-818000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3515000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3068000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1344000
ctkb Payment For Additional Investment In Cytek Japan Net Of Cash Acquired
PaymentForAdditionalInvestmentInCytekJapanNetOfCashAcquired
-371000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2697000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1344000
ctkb Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
4082000
ctkb Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
2772000
ctkb Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
-1310000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
215689000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
625000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
108000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
213542000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2880000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
625000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-13000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
210652000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5038000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166119000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30490000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
376771000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35528000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2238000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
765000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
309000
ctkb Intangible Asset In Accrued Expense
IntangibleAssetInAccruedExpense
90000
us-gaap Nature Of Operations
NatureOfOperations
<div style="display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:0.3402777777777778in;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.3402777777777778in;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description of business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cytek Biosciences, Inc. (“Cytek” or the “Company”) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. The Company has focused on becoming the premier cell analysis company through continued innovation that facilitates scientific advances in biomedical research and clinical applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The Company has successfully developed and manufactured its full spectrum flow cytometry platform (“instrument(s)” or “product(s)”). The Company believes its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells (“Full Spectrum Profiling” or “FSP”). The Company’s FSP platform includes instruments, accessories, reagents, software, and services to provide a comprehensive and integrated suite of solutions for its customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The Company was incorporated in the state of </span><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Delaware</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> in December 2014 and is headquartered in Fremont, California with offices, manufacturing facilities and distribution channels across the globe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">In July 2021, the Company priced its initial public offering (“IPO”) of </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">13,949,401</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> shares of common stock, which included the full exercise by the underwriters of their option to purchase an additional </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">2,184,695</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> shares from the Company, at an initial public offering price of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">17.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> per share for gross proceeds of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">237.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million, which resulted in net proceeds to the Company of approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">215.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts and commissions of approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">17.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million and offering-related transaction costs of approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million. In addition, certain selling stockholders offered and sold an additional </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">2,799,929</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> shares or common stock in the IPO. The Company did </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">t receive any proceeds from the sale of such shares by the selling stockholders.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.591%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3758333333333335;font-family:Times New Roman;margin-bottom:10.1pt;margin-right:0.093%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">In addition, in connection with the completion of the IPO on July 27, 2021, all outstanding shares of convertible preferred stock (see Note 10) were automatically converted into </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">87,268,694</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> shares of the Company’s common stock and were reclassified as permanent equity. Further, immediately following the closing of the IPO, the Company amended and restated its certificate of incorporation such that the total number of shares of common stock authorized to be issued was </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1,000,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> and the total number of shares of preferred stock authorized to be issued was </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">. Following the IPO, there are </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> shares of convertible preferred stock outstanding.</span></p>
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
0.50
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The preparation of the unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited interim consolidated financial statements and accompanying notes as of the date of the unaudited interim consolidated financial statements. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates.</span>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376800000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
165200000
CY2021Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q3 us-gaap Cash
Cash
15743000
CY2020Q4 us-gaap Cash
Cash
10651000
CY2021Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
361028000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
154580000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
888000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
376771000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166119000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
175000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
175000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
172000
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3000
ctkb Upfront And Payment Terms
UpfrontAndPaymentTerms
P30D
CY2021Q3 ctkb Offering Related Transaction Costs
OfferingRelatedTransactionCosts
5300000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
513000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
1200000
CY2020Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
215000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
705000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34376000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25096000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89056000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62220000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
34376000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25096000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89056000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62220000
CY2021Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
13626000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
29450000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16990000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13626000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7121000
CY2021Q3 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
562000
CY2020Q4 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
624000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14188000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7745000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5253000
CY2020 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
10678000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
13170000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7745000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
11585000
CY2021Q3 us-gaap Deferred Revenue
DeferredRevenue
18028000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14188000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
15366000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
12882000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1990000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3135000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10155000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7001000
CY2021Q3 us-gaap Inventory Gross
InventoryGross
27511000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
23018000
CY2021Q3 ctkb Prepaid Inventory
PrepaidInventory
286000
CY2020Q4 ctkb Prepaid Inventory
PrepaidInventory
29000
CY2021Q3 us-gaap Prepaid Rent
PrepaidRent
228000
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
162000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
2975000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
55000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1137000
CY2021Q3 ctkb Other Current Liabilities Other
OtherCurrentLiabilitiesOther
340000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
690000
CY2021Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
1373000
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
1114000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
95000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
445000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6094000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2495000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6617000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5563000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1199000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
359000
CY2021Q3 ctkb Accrued Purchases
AccruedPurchases
1174000
CY2020Q4 ctkb Accrued Purchases
AccruedPurchases
2065000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1646000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
969000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
117000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
92000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10753000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9048000
CY2021Q3 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
562000
CY2020Q4 ctkb Customer Deposit Liability Current
CustomerDepositLiabilityCurrent
624000
CY2020Q4 ctkb Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
2772000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
493000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
468000
CY2021Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
649000
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
566000
CY2020Q4 ctkb Other Current Liabilities Other
OtherCurrentLiabilitiesOther
196000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2044000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4626000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
154580000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
361028000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6472000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3074000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1490000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
934000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4982000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2140000
CY2021Q3 us-gaap Depreciation
Depreciation
192000
us-gaap Depreciation
Depreciation
553000
CY2020Q3 us-gaap Depreciation
Depreciation
163000
us-gaap Depreciation
Depreciation
381000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
855000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
764000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
494000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
490000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
361000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
274000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
64000
us-gaap Loss Contingency Lawsuit Filing Date
LossContingencyLawsuitFilingDate
February 13, 2018
ctkb Upfront Payment
UpfrontPayment
2000000.0
ctkb Royalty Payment Duration
RoyaltyPaymentDuration
P10Y
ctkb Mile Stone Payment
MileStonePayment
6000000.0
CY2021Q3 ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
940000
ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
2400000
CY2020Q3 ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
729000
ctkb Cost Of Sales Related To Royalty Expense
CostOfSalesRelatedToRoyaltyExpense
1700000
CY2021Q3 us-gaap Interest Expense
InterestExpense
441000
us-gaap Interest Expense
InterestExpense
1200000
CY2020Q3 us-gaap Interest Expense
InterestExpense
2000
us-gaap Interest Expense
InterestExpense
3000
CY2021Q3 ctkb Legal Settlement Liability Current
LegalSettlementLiabilityCurrent
7405000
CY2020Q4 ctkb Legal Settlement Liability Current
LegalSettlementLiabilityCurrent
6253000
CY2021Q3 ctkb Legal Settlement Liability Non Current
LegalSettlementLiabilityNonCurrent
12633000
CY2020Q4 ctkb Legal Settlement Liability Non Current
LegalSettlementLiabilityNonCurrent
10959000
CY2021Q3 ctkb Legal Settlement Liability
LegalSettlementLiability
20038000
CY2020Q4 ctkb Legal Settlement Liability
LegalSettlementLiability
17212000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6174778
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.67
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M14D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11405000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4315589
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1265730
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
294726
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.58
ctkb Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
5375
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.32
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8924536
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M21D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14597000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6001978
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y3M21D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
82765000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2922558
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
66832000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.56
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.62
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
323000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
191000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
628000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
297000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2455000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
126000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3578000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
340000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8983
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8520
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9007
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8054
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0088
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0095
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0075
CY2021Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
205000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
572000
CY2020Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
159000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
432000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.316
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.237
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.052
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-1.149
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1760000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2104000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2453000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2208000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2145000
CY2021Q3 ctkb Lessee Operating Lease Liability Payments Due Year Four And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter
6734000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17404000
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
442000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1300000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
335000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
909000
CY2020Q2 us-gaap Proceeds From Loan Originations1
ProceedsFromLoanOriginations1
4100000
CY2020Q2 ctkb Average Monthly Payroll Expense
AverageMonthlyPayrollExpense
2.5
CY2020Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
969000
CY2019Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
734000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
2841000
CY2020 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
1506000
us-gaap Product Warranty Expense
ProductWarrantyExpense
2164000
CY2020 us-gaap Product Warranty Expense
ProductWarrantyExpense
1271000
CY2021Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
1646000
CY2020Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
969000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
1420000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
6540000
us-gaap Net Income Loss
NetIncomeLoss
4192000
us-gaap Net Income Loss
NetIncomeLoss
13812000
CY2021Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-1074000
CY2020Q3 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-5094000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-4192000
us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-11171000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
346000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1446000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2641000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108322433
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28700005
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57534080
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28551126
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5314945
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2358752
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4561195
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2212461
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113637377
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31058757
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62095275
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30763586
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.003198
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.050354
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.092443
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.003048
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.046530
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.085794
CY2021Q3 us-gaap Revenues
Revenues
34376000
CY2020Q3 us-gaap Revenues
Revenues
25096000
us-gaap Revenues
Revenues
89056000
us-gaap Revenues
Revenues
62220000
CY2021Q3 us-gaap Noncurrent Assets
NoncurrentAssets
4982000
CY2020Q4 us-gaap Noncurrent Assets
NoncurrentAssets
2140000

Files In Submission

Name View Source Status
0000950170-21-004256-index-headers.html Edgar Link pending
0000950170-21-004256-index.html Edgar Link pending
0000950170-21-004256.txt Edgar Link pending
0000950170-21-004256-xbrl.zip Edgar Link pending
ctkb-20210930.htm Edgar Link pending
ctkb-20210930.xsd Edgar Link pending
ctkb-20210930_cal.xml Edgar Link unprocessable
ctkb-20210930_def.xml Edgar Link unprocessable
ctkb-20210930_htm.xml Edgar Link completed
ctkb-20210930_lab.xml Edgar Link unprocessable
ctkb-20210930_pre.xml Edgar Link unprocessable
ctkb-ex10_1.htm Edgar Link pending
ctkb-ex10_2.htm Edgar Link pending
ctkb-ex31_1.htm Edgar Link pending
ctkb-ex31_2.htm Edgar Link pending
ctkb-ex32_1.htm Edgar Link pending
ctkb-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending